Somatic characteristics and cardiovascular risk factors in growth hormone deficiency: a randomized, double-blind, placebo-controlled study of the effect of treatment with recombinant human growth hormone.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The purpose of the present study was to identify the effect of treatment with recombinant human growth hormone (rhGH) on seven somatic characteristics and eight clinical cardiovascular risk factors.

Why It Was Studied

Twenty-seven male and 24 female patients between the ages of 21 and 60 years were examined.

The investigation was a double-blind, placebo-controlled study of 12 months duration.

Who Took Part

The abstract describes 24 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Patients were assigned randomly to treatment (T) and placebo (P) groups.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Age Distribution, Anthropometry, Body Composition, Body Height, Cardiovascular Diseases, Growth Disorders and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (American journal of human biology : the official journal of the Human Biology Council), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.